Comments on: Flow Cytometric Profiling Reveals Platelet Dysfunction and Impaired Immune Communication in Acute and Chronic Cerebrovascular Disease Authors: Rajesh Prasad Jayaswal, Azeem Rizvi, Javed Siddiqui, Maajid Mohi Ud Din Malik Published: 2026 To the Editor, Shen et al. [1] should be congratulated for a timely and clinically relevant contribution to cerebrovascular laboratory medicine. Their flow cytometric profiling of PAC‐1 expression, P‐selectin response, and platelet‐leukocyte interactions across acute and chronic cerebrovascular disease moves the discussion beyond platelet count and routine coagulation assays toward functional thromboimmune phenotyping. The strength of the article lies in its laboratory‐to‐clinic orientation: It invites clinical laboratories to consider whether platelet activation and platelet‐immune communication can become measurable, reproducible, and interpretable signals of neurovascular injury. This is highly aligned with the readership of the Journal of Clinical Laboratory Analysis, because the paper converts a specialized cellular assay into a practical question of diagnostic standardization, quality assurance, and clinical implementation. The most important implication of the study is not only that platelet dysfunction can be detected in cerebrovascular disease, but that platelet flow cytometry may serve as a disease‐state translator when interpreted within existing methodological standards. Recent ISTH Scientific and Standardization Committee guidance in the Journal of Thrombosis and Haemostasis has already emphasized standardization of platelet flow cytometry with respect to sample collection, preanalytical variables, sample type, platelet‐count considerations, result expression, and reporting [2]. Similarly, contemporary laboratory guidance highlights the importance of protocol optimization for platelet phenotype, function, and cellular‐interaction assays [3]. Shen et al. [1] therefore provide a disease‐specific opportunity to apply these broader platelet‐flow‐cytometry principles to stroke biology. The challenge is to avoid treating PAC‐1, CD62P/P‐selectin, and platelet‐leukocyte aggregates as isolated biomarkers; rather, they should be interpreted as pathway‐linked readouts influenced by agonist selection, antiplatelet exposure, inflammation, diabetes, renal dysfunction, infection, timing after symptom onset, and sample handling. Although these findings are compelling, they should remain hypothesis‐generating. The single‐center design, sample size, and clinical heterogeneity across cerebrovascular subgroups may limit generalizability and make universal decision thresholds premature. These constraints strengthen the case for prospectively powered multicenter validation with prespecified subgroup analyses and harmonized preanalytical and analytical procedures. A more practical validation pathway could be organized as a Stroke Platelet Flow Cytometry Harmonization Framework with five sequential phases. Phase 1 should lock down preanalytical conditions, including venipuncture technique, anticoagulant, time‐to‐staining, temperature, transport, fixation, whole‐blood versus platelet‐rich‐plasma strategy, platelet count adjustment, and exclusion of ex vivo activation. Phase 2 should define a core agonist panel: ADP to interrogate P2Y12‐dependent amplification, TRAP‐6 to evaluate PAR1‐mediated thrombin signaling, collagen or convulxin to assess GPVI pathways, and arachidonic acid where cyclooxygenase‐thromboxane biology or aspirin response is relevant. Experimental evidence shows that leukocyte‐platelet aggregate formation differs substantially according to cellular stimulant and that platelet activation can be the restrictive step for aggregate formation [4]. High‐dimensional platelet phenotyping further demonstrates that platelet subpopulations remodel dynamically after ADP, TRAP‐6, and convulxin stimulation and under inhibitor exposure [5, 6]. Thus, a future cerebrovascular panel should not use a single marker‐single agonist approach; it should report pathway‐specific platelet reactivity, platelet‐leukocyte aggregate composition, and clinically meaningful response patterns. Phase 3 should establish analytical harmonization, including instrument calibration, fluorescence compensation, antibody clone selection, fluorescence‐minus‐one controls, calibration beads, gating templates, operator training, inter‐run precision, and external quality assessment. Phase 4 should test multicenter reproducibility and clinical validity in prospective cohorts stratified by ischemic stroke, intracerebral hemorrhage, transient ischemic attack, chronic cerebrovascular disease, antiplatelet regimen, and time from onset. Phase 5 should evaluate implementation in routine practice by linking platelet‐flow‐cytometry signatures with neurological deterioration, recurrent vascular events, antiplatelet responsiveness, rehabilitation outcomes, mortality, cost, and turnaround time. Experience from other vascular settings supports this stepwise approach: immature platelet reactivity remains clinically relevant after ST‐segment elevation myocardial infarction despite antiplatelet therapy [7], and platelet‐leukocyte aggregates have been studied as diagnostic, prognostic, and treatment‐monitoring biomarkers across cardiovascular diseases [8]. These observations suggest that stroke laboratories can learn from cardiology and thrombosis laboratories rather than beginning validation de novo. Feasibility should also be treated as an analytical endpoint rather than an aspirational principle. Resource‐constrained laboratories could initially adopt a tiered model based on low‐volume whole‐blood testing, a minimal clinically informative antibody/agonist panel, standardized same‐day processing, and referral‐center support for instrument calibration and external quality assessment. Multicenter studies should prospectively record hands‐on time, sample‐to‐result time, repeat‐test frequency, reagent consumption, instrument requirements, and cost per reportable result alongside diagnostic performance; otherwise, analytical validity may not translate into scalable clinical utility. The future research agenda should also be global and implementation‐conscious. Stroke burden remains high worldwide, with major inequities in prevention, diagnosis, and outcomes [9]. If platelet flow cytometry remains available only in tertiary referral centers, it may widen rather than reduce diagnostic disparities. Future studies should therefore include low‐volume whole‐blood protocols, simplified staining panels for resource‐limited laboratories, open gating templates, reference materials, cloud‐based external quality assessment, and explainable machine‐learning models that remain auditable by laboratory professionals. Mechanistic reviews of stroke thromboinflammation reinforce the need to integrate platelet, leukocyte, endothelial, and inflammatory signals rather than evaluating hemostasis in isolation [10]. In conclusion, Shen et al. [1] have provided a strong platform for moving platelet phenotyping from descriptive neurovascular biology toward accountable laboratory medicine. This letter aims to support that translational step by proposing a standards‐based, multicenter, and equity‐focused pathway through which platelet flow cytometry may become a future‐ready tool for cerebrovascular precision diagnostics. Author Contributions Conceptualization: R.P.J.; formal analysis: A.R. and M.M.U.D.M.; writing – original draft: R.P.J.; writing – review and editing: R.P.J., J.S., and M.M.U.D.M.; supervision: J.S. All authors reviewed and approved the final manuscript. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors acknowledge the contribution of the investigators of the targeted article for advancing translational cerebrovascular laboratory medicine. AI‐assisted language tools were used only for language refinement and manuscript formatting. All scientific interpretation, critical analysis, reference verification, and final approval were performed by the authors. No AI tool generated original data or qualifies for authorship. The authors accept full responsibility for the integrity and originality of the manuscript. Data Availability Statement Data sharing is not applicable to this article because no datasets were generated or analyzed. References Associated Data Data Availability Statement Data sharing is not applicable to this article because no datasets were generated or analyzed.